Flonase Sensimist Allergy Relief is owned by Glaxosmithkline Cons.
Flonase Sensimist Allergy Relief contains Fluticasone Furoate.
Flonase Sensimist Allergy Relief has a total of 5 drug patents out of which 0 drug patents have expired.
Flonase Sensimist Allergy Relief was authorised for market use on 02 August, 2016.
Flonase Sensimist Allergy Relief is available in spray, metered;nasal dosage forms.
The generics of Flonase Sensimist Allergy Relief are possible to be released after 15 October, 2028.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9320862 | GLAXOSMITHKLINE CONS | Fluid dispensing device |
Nov, 2024
(1 year, 7 months from now) | |
US8752543 | GLAXOSMITHKLINE CONS | Fluid dispensing device |
Apr, 2026
(3 years from now) | |
US8062264 | GLAXOSMITHKLINE CONS | Fluid dispensing device |
Apr, 2026
(3 years from now) | |
US8347879 | GLAXOSMITHKLINE CONS | Fluid dispensing device |
Jul, 2028
(5 years from now) | |
US8147461 | GLAXOSMITHKLINE CONS | Fluid dispensing device |
Oct, 2028
(5 years from now) |
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 02 August, 2016
Treatment: NA
Dosage: SPRAY, METERED;NASAL
10
United Kingdom
9
European Union
8
Australia
8
United States
8
China
8
Japan
5
South Africa
5
Brazil
5
Canada
4
Denmark
4
Austria
4
Hong Kong
4
Portugal
4
Cyprus
4
Spain
4
Poland
4
New Zealand
3
Israel
3
Mexico
3
Norway
3
Germany
3
Korea, Republic of
2
Singapore
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic